证券之星消息，1月6日医疗美容板块较上一交易日上涨0.66%，爱美客领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 146.49 | 1.06% | 3.41万 | 4.98 乙 | | 688363 | 华熙生物 | 44.91 | 0.34% | 5.16万 | 2.31亿 | | 920982 | 锦波生物 | 236.12 | -0.22% | 7324.94 | 1.74亿 | | 000615 | *ST美谷 | 3.46 | -0.86% | 13.90万 | 4782.12万 | 从资金流向上来看，当日医疗美容板块主力资金净流出1283.62万元，游资资金净流入772.62万元，散户 资金净流入511.0万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | | | 主力净占比 游资净流入 ...

证券之星消息，1月5日医疗美容板块较上一交易日上涨2.22%，华熙生物领涨。当日上证指数报收于 4023.42，上涨1.38%。深证成指报收于13828.63，上涨2.24%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688363 | 华熙生物 | 44.76 | 2.47% | 4.79万 | 2.14亿 | | 300896 | 爱美客 | 144.95 | 2.28% | 3.97万 | 5.72亿 | | 920982 | 锦波生物 | 236.64 | 1.26% | 7690.59 | 1.80 Z | | 000615 | *ST美谷 | 3.49 | 0.00% | 11.32万 | 3982.21万 | 从资金流向上来看，当日医疗美容板块主力资金净流入1362.9万元，游资资金净流出704.42万元，散户资 金净流出658.47万元。医疗美容板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345 ...

Core Viewpoint - The medical beauty sector experienced a decline of 0.97% on December 29, with Ai Meike leading the drop, while the overall Shanghai Composite Index rose slightly by 0.04% [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3965.28, and the Shenzhen Component Index closed at 13537.1, down by 0.49% [1] - The medical beauty sector's individual stock performance showed varied results, with *ST Meigu leading with a rise of 5.10% to a closing price of 3.71, while Ai Meike fell by 2.29% to 141.03 [1] Group 2: Capital Flow - The medical beauty sector saw a net outflow of 74.18 million yuan from main funds, while retail investors contributed a net inflow of 29.66 million yuan [1] - Individual stock capital flow indicated that Ai Meike had a significant net outflow of 74.86 million yuan from main funds, despite a net inflow of 36.80 million yuan from retail investors [2]

截至12月26日，北交所融资融券余额合计79.79亿元，较前一交易日增加2788.90万元，其中，融资余额 79.79亿元，较前一交易日增加2791.38万元，融券余额为25.02万元，较前一交易日减少2.48万元。 | 920571 | 国航远 | -0.69 | 5087.27 | 166.37 | 1.80 | 交通运 | | --- | --- | --- | --- | --- | --- | --- | | | 洋 | | | | | 输 | | 920665 | 科强股 | -2.31 | 1443.47 | 164.82 | 1.52 | 基础化 | | | 份 | | | | | 工 | | 920719 | 宁新新 | 0.00 | 1027.46 | 163.70 | 1.08 | 基础化 | | | 材 | | | | | 工 | | 920068 | 天工股 | -4.79 | 3747.19 | 157.51 | 2.98 | 有色金 | | | 份 | | | | | 属 | | 920418 | 苏轴股 | | | | | 汽车 | | | 份 | -1.72 | 8246.2 ...

Core Viewpoint - Shanxi Jinbo Biological Pharmaceutical Co., Ltd. plans to increase its investment in its wholly-owned subsidiary, Jinbo Medical, by 165 million yuan to support strategic development and business needs [1] Group 1: Investment Details - The registered capital of Jinbo Medical will increase from 35 million yuan to 200 million yuan following the capital increase [1] - The funding for this capital increase will come from the company's own funds and loans from new policy-based financial instruments, with no new shareholders involved [1] Group 2: Subsidiary Overview - Jinbo Medical, established on January 31, 2023, is located in Daxing District, Beijing, and its business scope includes the production of cosmetics, sanitary products, disposable medical supplies, and Class III medical devices [1] - As of September 30, 2025, Jinbo Medical's unaudited total assets are approximately 99.08 million yuan, with net assets around 30.60 million yuan [1] Group 3: Project Information - Jinbo Medical is the main entity for implementing the "Humanized Collagen FAST Database and Product Development Platform Project" of Jinbo Biological, which is currently under construction and has not yet generated operating income [1]

Core Insights - As of December 24, the total margin financing and securities lending balance on the Beijing Stock Exchange reached 7.959 billion yuan, an increase of 71.38 million yuan from the previous trading day, marking a continuous increase for four consecutive trading days [1] - The stocks with the highest margin financing balances include Jinbo Biological, Shuguang Digital Innovation, and Better Energy, with latest balances of 399 million yuan, 370 million yuan, and 339 million yuan respectively [1] - A total of 182 stocks on the Beijing Stock Exchange received net margin purchases on December 24, with 44 stocks having net purchases exceeding 1 million yuan, led by Tianli Composite with a net purchase of 9.5846 million yuan [1][2] Margin Financing Overview - The margin financing balance increased for the following stocks on December 24: - Tianli Composite: 572.73 million yuan, up by 9.5846 million yuan, with a market value ratio of 0.67% [2] - Tiangong Co.: 321.16 million yuan, up by 6.5918 million yuan, with a market value ratio of 2.46% [2] - Hongyu Packaging: 254.18 million yuan, up by 6.407 million yuan, with a market value ratio of 0.83% [2] Industry Performance - The industries with the highest concentration of stocks receiving net margin purchases over 1 million yuan include machinery equipment, automotive, and basic chemicals, with 6, 5, and 4 stocks respectively [2] - On December 24, stocks with net margin purchases exceeding 1 million yuan had an average increase of 0.98%, with notable gainers including Tiangong Co. (up 16.15%), Jiahe Technology (up 9.60%), and Litong Technology (up 6.73%) [2] - The average turnover rate for stocks with net margin purchases over 1 million yuan was 4.60%, with the highest turnover rates seen in Tiangong Co. (38.53%), Xingchen Technology (21.24%), and Knight Dairy (18.00%) [2]

证券代码：920982 证券简称：锦波生物 公告编号：2025-185 山西锦波生物医药股份有限公司 关于拟向全资子公司增加注册资本的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、对外投资概述 （一）基本情况 根据公司战略发展规划及业务发展需要，公司拟向全资子公司锦波医学生 物材料（北京）有限公司（以下简称"锦波医学"）增资人民币 16,500 万元， 本次增资完成后锦波医学的注册资本由人民币 3,500 万元增加至人民币 20,000 万元。 （二）是否构成重大资产重组 本次交易不构成重大资产重组。 根据《上市公司重大资产重组管理办法》的相关规定，本次对外投资系对 全资子公司增资，不构成重大资产重组。 （七）投资对象是否开展或拟开展私募投资活动 本次交易标的不涉及开展或拟开展私募投资活动，不是已在中国证券投资基 金业协会登记为私募基金管理人，不会将公司主营业务变更为私募基金管理业务。 （三）是否构成关联交易 本次交易不构成关联交易。 （四）决策与审议程序 公司于 2025 年 12 月 2 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 证券代码：920982 证券简称：锦波生物 公告编号：2025-184 （一）会议召开情况 1.会议召开时间：2025 年 12 月 23 日 山西锦波生物医药股份有限公司 第四届董事会第十八次会议决议公告 4.发出董事会会议通知的时间和方式：2025 年 12 月 20 日以邮件方式发出 5.会议主持人：董事长杨霞女士 6.会议列席人员：薛芳琴、兰小宾 7.召开情况合法合规的说明： 本次会议的召集、召开、审议过程符合《中华人民共和国公司法》等有关法 律、行政法规、部门规章、规范性文件及《公司章程》的规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事陈镔、王玲玲、阎丽明、梁桐栋、邓泽林因出差或外地办公以通讯方式 参与表决。 二、议案审议情况 2.会议召开地点：公司四楼会议室 3.会议召开方式：现场加通讯 4.提交股东会表决情况： 本议案无需提交股东会审议。 （二）审议通过《关于拟向全资子公司增加注 ...

Core Viewpoint - The medical beauty sector experienced a decline of 1.37% on December 23, with Ai Meike leading the drop, while the overall market indices showed slight increases [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3919.98, up 0.07% [1] - The Shenzhen Component Index closed at 13368.99, up 0.27% [1] - The medical beauty sector saw a net outflow of 64.78 million yuan from main funds, while retail investors contributed a net inflow of 39.45 million yuan [1] Group 2: Individual Stock Performance - Jinbo Biological (code: 920982) closed at 249.76, with a gain of 1.33% and a trading volume of 88,613.2 hands, totaling 218 million yuan [1] - ST Meigu (code: 000615) closed at 4.18, down 0.95% with a trading volume of 215,700 hands, totaling 9.28 million yuan [1] - Huaxi Biological (code: 688363) closed at 43.48, down 1.29% with a trading volume of 24,700 hands, totaling 108 million yuan [1] - Ai Meike (code: 300896) closed at 142.29, down 1.46% with a trading volume of 28,000 hands, totaling 400 million yuan [1] Group 3: Fund Flow Analysis - Jinbo Biological saw a main fund net inflow of 6.66 million yuan, with a main fund net ratio of 3.05% [2] - ST Meigu experienced a main fund net outflow of 1.76 million yuan, with a net inflow from retail investors of 2.50 million yuan [2] - Huaxi Biological had a main fund net outflow of 14.61 million yuan, with a retail net inflow of 6.11 million yuan [2] - Ai Meike faced a significant main fund net outflow of 48.42 million yuan, while retail investors contributed a net inflow of 30.84 million yuan [2]

Group 1 - The report highlights the performance of the North Exchange in 2025, indicating a significant rise in the North Index 50 to around 1400 points, with three distinct phases of market movement: rapid increase, oscillating rise, and a correction phase [2][12][15] - In the rapid increase phase (January 1 - March 11, 2025), the North Index 50 surged from 1,037.81 to 1,418.65 points, achieving a cumulative return of 36.70%, while the specialized index rose from 1,683.33 to 2,421.50 points, with a return of 43.85% [15][16] - The oscillating rise phase (April 7 - September 5, 2025) saw the North Index 50 increase from 1,044.07 to 1,647.01 points, yielding a cumulative return of 58.70%, and the specialized index from 1,759.64 to 2,806.39 points, with a return of 66.72% [16][17] Group 2 - The correction phase (September 15 - December 19, 2025) stabilized the North Index 50 and specialized index around 1400 and 2400 points, respectively, with the North Index 50 declining to 1,445.84 points and the specialized index to 2,440.21 points, resulting in cumulative returns of 39.32% and 44.96% [17][23] - The report emphasizes the performance of small-cap stocks, indicating that companies with market capitalizations of 0-20 billion, 20-40 billion, 40-80 billion, and above 80 billion had average returns of 54.08%, 38.60%, 18.26%, and 30.59%, respectively [26][31] - The report identifies that national and provincial-level "little giant" companies outperformed non-little giant firms, with average returns of 48.26%, 38.06%, and 39.19% for national, provincial, and non-little giants, respectively [27][29] Group 3 - The report highlights that national and provincial-level single champion companies achieved average returns of 59.27% compared to 39.61% for non-single champion companies [32][34] - In terms of industry performance, high-end equipment and new chemical materials sectors showed higher returns, with average returns of 50.20%, 28.67%, 48.49%, 40.43%, and 43.56% for high-end equipment, information technology, new chemical materials, consumer services, and biomedicine, respectively [34][36] - The report also notes that companies with new productive forces, ESG attributes, high scarcity, and high dividends had average returns of 50.49%, 48.44%, 49.14%, and 57.51%, respectively, indicating a strong performance in these categories [37][43]